Next, we compared the duration of the OS and DFS periods between groups of patients with tumours that had: (1) mutations in genes of only one of the four MAPK pathway modules (i.e., the ERK1/2, ERK5, p38 or JNK pathways), (2) in genes of more than one of the MAPK pathway modules (3) or with no mutations in any MAPK pathway genes. This evidence concerns the gene MAPK14 and neoplasm.